New Antibody-Drug Reduces Death in High-Risk Pandemic Patients

Drugs are being developed every day around the world.

Since the pandemic, many companies around the world have been developing treatments to fight the SARS-CoV-2 virus. A year ago, over 130 potential drugs were being evaluated in over one thousand clinical trials.

Antivirals, immune modulators, and many more can be found in this link –

Monoclonal Antibody Drugs Some monoclonal antibodies (mAbs) focus on immune system response (cytokine storm), while others concentrate on neutralizing the COVID-19 viral protein structure.

A cytokine storm results when our immune system is overwhelmed. IL6 (interleukin 6) promotes inflammation. Current mAbs drugs, such as tocilizumab, sarilumab, and siltuximab, are being used to treat patients with high levels of IL6.

New mAbs Drug Soltrovimab has received EUA (emergency use authorization) from the U. S. Food and Drug Administration last month and is used to treat high-risk non-hospitalized patients with mild-to-moderation coronavirus.

The Study Over one thousand patients destined for hospitalization were treated with sotrovimab. Nearly 80% recovered sufficiently to remain at home and continue treatment. This mAbs treatment is currently given via an intravenous drip. Studies are underway to convert the IV drip to an intramuscular shot.


This class of mAbs drugs helps our bodies fight off infection and inflammation. Fourteen antiviral drugs, 33 mAbs (and related) drugs, and 23 mixed mechanism treatments are being used in various clinical and non-clinical tests. These do not include over 100 vaccines in development around the world.

Lots of research, testing, and evaluation are being done to fight COVID-19. Many of these treatments might be used to treat other diseases. For example, I recently read an article about mRNA technology to treat some types of cancers.

Live Longer & Enjoy Life! – Red O’Laughlin –


Leave a Reply

Your email address will not be published. Required fields are marked *

CommentLuv badge

This site uses Akismet to reduce spam. Learn how your comment data is processed.